Trials / Available
AvailableNCT03865836
Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease
Named Patient or Compassionate Use for Treatment Use of ATB200/AT2221 for Patients With Pompe Disease
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Amicus Therapeutics · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200/AT2221.
Detailed description
This program is being offered on a patient by patient basis and will require company, IRB/IEC and single patient IND approval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ATB200 | |
| DRUG | AT2221 |
Timeline
- First posted
- 2019-03-07
- Last updated
- 2025-09-15
Source: ClinicalTrials.gov record NCT03865836. Inclusion in this directory is not an endorsement.